Detalhe da pesquisa
1.
CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory.
Proc Natl Acad Sci U S A
; 119(7)2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35140181
2.
Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.
Cancer Sci
; 105(8): 1040-8, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24837299
3.
Design, synthesis, and binding mode prediction of 2-pyridone-based selective CB2 receptor agonists.
Bioorg Med Chem
; 21(7): 2045-55, 2013 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23395112
4.
Selective CB2 agonists with anti-pruritic activity: discovery of potent and orally available bicyclic 2-pyridones.
Bioorg Med Chem
; 21(11): 3154-63, 2013 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23623258
5.
S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells.
Mol Cancer Ther
; 22(9): 1063-1072, 2023 09 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37420296
6.
Distribution analysis of epertinib in brain metastasis of HER2-positive breast cancer by imaging mass spectrometry and prospect for antitumor activity.
Sci Rep
; 8(1): 343, 2018 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29321587
7.
2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 1: discovery of CB2 receptor selective compounds.
Bioorg Med Chem Lett
; 17(14): 4030-4, 2007 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17521907